Results 171 to 180 of about 6,300 (191)
Some of the next articles are maybe not open access.
Current strategies with high-dose tirofiban
Expert Opinion on Drug Metabolism & Toxicology, 2007The glycoprotein (GP) IIb/IIIa receptor is a platelet-specific adhesion receptor that mediates the formation of platelet aggregates. Pharmacologic blockade of the receptor is associated with a reduction in major cardiovascular adverse events after percutaneous coronary interventions and in the setting of acute coronary syndromes.
Marco Roffi, Debabrata Mukherjee
openaire +3 more sources
The Effect of Tirofiban on Microvascular Thrombosis: Crush Model
Plastic and Reconstructive Surgery, 2005Microvascular anastomotic thrombosis is a significant clinical problem, particularly in crush and avulsion injuries. Platelet deposition plays a particularly important role in the initiation and propagation of microvascular thrombosis, whereas thrombin has little effect in the acute phase of thrombus formation.
Carlos L. Farias +4 more
openaire +3 more sources
Drugs, 1998
Tirofiban is an intravenously administered nonpeptide glycoprotein IIb/IIIa receptor antagonist which specifically inhibits fibrinogen-dependent platelet aggregation and prolongs bleeding times in patients with acute coronary syndromes. Adenosine diphosphate (ADP)-induced platelet aggregation returns to near-baseline levels within 4 to 8 hours after ...
Karen L. Goa, Karen J. McClellan
openaire +3 more sources
Tirofiban is an intravenously administered nonpeptide glycoprotein IIb/IIIa receptor antagonist which specifically inhibits fibrinogen-dependent platelet aggregation and prolongs bleeding times in patients with acute coronary syndromes. Adenosine diphosphate (ADP)-induced platelet aggregation returns to near-baseline levels within 4 to 8 hours after ...
Karen L. Goa, Karen J. McClellan
openaire +3 more sources
Synthesis and biological evaluation of PEG-tirofiban conjugates
Bioorganic & Medicinal Chemistry Letters, 2008We have conjugated tirofiban, an antagonist of the GPIIb/IIIa integrin receptor, to PEG, and shown that these polymers effectively inhibit platelet aggregation. This inhibition decreased with the size of the polymer. Our goal was to develop new cryoprotective agents to store frozen platelets.
Jean-Pierre Cazenave +3 more
openaire +3 more sources
Tirofiban-induced diffuse alveolar haemorrhage
BMJ Case ReportsA middle-aged man presented with inferior wall ST-elevation myocardial infarction and underwent primary percutaneous coronary intervention with tirofiban administered due to extensive thrombus. He developed sudden-onset dyspnoea, bilateral crepitations, haemoptysis, desaturation and hypotension an hour after starting tirofiban infusion.
Bryan, Sebastian +2 more
openaire +2 more sources
Tirofiban in emergency conditions
The American Journal of Emergency Medicine, 2022Aleksandra Gasecka +4 more
openaire +2 more sources
Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban
Vascular Pharmacology, 2016Glycoprotein (GP) IIb/IIIa inhibitors block platelet aggregation, reducing thrombotic events in acute coronary syndrome. They are most often utilized in patients who likely have an intracoronary thrombus. Tirofiban, eptifibatide, and abciximab are the three GP IIb/IIIa inhibitors approved for use in the United States.
Marintha Short +2 more
openaire +3 more sources
The Role of Tirofiban in the Management of Coronary Artery Disease
Cardiovascular & Hematological Disorders-Drug Targets, 2008Glycoprotein IIb/IIIa receptor antagonists are potent antiplatelet agents by inhibiting the final common pathway of platelet aggregation. Tirofiban binds specifically to the glycoprotein IIb/IIIa receptor resulting in immediate and extensive inhibition of platelets.
Craig P. Juergens, Julian P Winter
openaire +3 more sources
The American Journal of Cardiology, 2003
P in the do Tirofiban And Reopro Give similar Efficacy outcomes Trial (TARGET) treated with abciximab compared with tirofiban had a lower 30-day incidence of the combined end point of death, myocardial infarction, and target vessel revascularization that reflected, in large part, a decrease in the incidence of periprocedural myocardial infarction.1 We ...
Kuo Chang Yin +8 more
openaire +3 more sources
P in the do Tirofiban And Reopro Give similar Efficacy outcomes Trial (TARGET) treated with abciximab compared with tirofiban had a lower 30-day incidence of the combined end point of death, myocardial infarction, and target vessel revascularization that reflected, in large part, a decrease in the incidence of periprocedural myocardial infarction.1 We ...
Kuo Chang Yin +8 more
openaire +3 more sources
Tirofiban: a breakthrough in treating unstable angina
Inpharma Weekly, 1997Adding the glycoprotein IIb/IIIa receptor antagonist tirofiban # to standard treatment for patients with unstable angina pectoris and non-Q-wave myocardial infarction (MI) can significantly reduce ischaemic complications, note researchers from the PRISM * and PRISM-plus *
openaire +2 more sources